OpenAI acquires Orchestra Bio for its Rosalind life-sciences work
Original title: OpenAI acquires startup Orchestra Bio to beef up its biotech business
Terms were undisclosed; the four-year-old startup had reportedly raised about $20 million by 2025.
OpenAI said Tuesday it acquired Orchestra Bio, a four-year-old startup whose agents help biotech companies handle drug-discovery operations. OpenAI plans to add Orchestra’s team and technology to Rosalind, its life-sciences model, and to Rosalind Workbench. OpenAI says Rosalind customers include Moderna and Novo Nordisk.
Unconfirmed: Deal terms were not disclosed, and the roughly $20 million funding figure is reported rather than confirmed here.
- Orchestra’s agents cover finances and clinical-trial scheduling.
- Reported backers include Andreessen Horowitz, Atria, and 8VC.
- Rosalind Workbench is meant to plan experiments and analyze results.
- Products
- Rosalind Workbench
- Organizations
- OpenAIOrchestra BioModernaNovo Nordisk
- AI models
- Rosalind
From the original article
1 min read at techcrunch.com
OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.
By Julie Bort · techcrunch.com
A short excerpt; the article and its images belong to the publisher. Summary, key facts and assessment above are AI-written from the article and can be wrong.